论文部分内容阅读
目的探讨丁苯酞治疗急性脑梗死的临床疗效以及对患者血清超敏C-反应蛋白(hs CRP)的影响。方法随机选取2012年8月至2014年11月收治的急性脑梗死病例60例,平均分为观察组30例,对照组30例,对照组予以常规治疗,观察组在此基础上加用丁苯酞注射液,治疗前及经治疗14天后分别对两组病例进行血清hs CRP检测。对比两组患者治疗前后的临床疗效、神经功能缺损评分(NIHSS)及hs CRP水平。结果经14天治疗后,观察组治疗总有效率为96.7%,显著高于对照组的73.3%,两组对比差异有统计学意义(P<0.05);观察组NIHSS评分及血清hs CRP水平均显著低于对照组(P<0.05)。结论丁苯酞能够显著降低急性脑梗死患者血清hs CRP水平,抑制炎性反应,改善脑梗死患者的病情及预后,值得临床推广。
Objective To investigate the clinical efficacy of butylphthalide in the treatment of acute cerebral infarction and its effect on serum hs-CRP in patients. Methods Sixty cases of acute cerebral infarction were randomly selected from August 2012 to November 2014. The average score was divided into observation group (30 cases) and control group (30 cases). The control group was given routine treatment. On the basis of this observation, the observation group was given SBE Phthalide injection, before treatment and after 14 days of treatment, respectively, two groups of patients serum hs CRP detection. The clinical efficacy, neurological deficit score (NIHSS) and hs CRP levels were compared between the two groups before and after treatment. Results After 14 days of treatment, the total effective rate of the observation group was 96.7%, significantly higher than that of the control group (73.3%), the difference between the two groups was statistically significant (P <0.05); NIHSS score and serum hs CRP level Significantly lower than the control group (P <0.05). Conclusion Butylphthalide can significantly reduce serum hs CRP levels in patients with acute cerebral infarction, inhibit inflammatory responses and improve the prognosis of patients with cerebral infarction, worthy of clinical promotion.